Are Medical Stocks Lagging Entera Bio (ENTX) This Year?

Group 1 - Entera Bio Ltd. (ENTX) has significantly outperformed the Medical sector with a year-to-date return of 336.7%, compared to an average gain of 5.6% for Medical stocks [4] - The Zacks Rank for Entera Bio Ltd. is currently 2 (Buy), indicating strong analyst sentiment and an improving earnings outlook, with a 66.7% increase in the consensus estimate for full-year earnings over the past quarter [3] - Entera Bio Ltd. is part of the Medical - Biomedical and Genetics industry, which includes 506 companies and currently ranks 92 in the Zacks Industry Rank, while the average performance of this group has been a loss of 2.4% this year [5] Group 2 - Assembly Biosciences (ASMB) is another Medical stock that has outperformed the sector with a year-to-date return of 48.4% and also holds a Zacks Rank of 2 (Buy) [4][5] - The consensus EPS estimate for Assembly Biosciences has increased by 14.3% over the past three months, reflecting positive analyst sentiment [5] - The Medical - Generic Drugs industry, to which Assembly Biosciences belongs, has seen a year-to-date increase of 11.1% and currently ranks 52 [6]